Home › Blood Disorders › Alabama › Birmingham
Blood Disorders clinical trials in Birmingham, AL
4 studies for Blood Disorders are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RecruitingPhase 3
- University Of Alabama, Birmingham
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
- Quetzal Site 16, Birmingham
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Recruiting
- University of Alabama at Brimingham, Birmingham
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- University of Alabama at Birmingham, Birmingham
About Blood Disorders
Blood disorders affect one or more parts of the blood and prevent your blood from doing its job. Find out about the types, causes, and treatments.
More about Blood Disorders on MedlinePlus
Blood Disorders trials in other cities
- Boston, MA10 studies
- Atlanta, GA10 studies
- Houston, TX9 studies
- Los Angeles, CA9 studies
- The Bronx, NY8 studies
- New York City, NY7 studies
- Nashville, TN7 studies
- Mountain View, CA6 studies
- Durham, NC5 studies
- Portland, OR5 studies
- Washington, DC5 studies
- Seattle, WA5 studies
Other studies in Birmingham
- Cancer (all types)30 studies
- Breast Cancer24 studies
- Obesity23 studies
- Ovarian Cancer23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- Multiple Myeloma18 studies
- COPD17 studies
- Cardiovascular Disease17 studies
- Overweight16 studies
- Endometrial Cancer16 studies
- Type 2 Diabetes16 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.